Ravaud, A., Motzer, R. J., Pandha, H. S., Staehler, M., George, D., Pantuck, A. J., … Patard, J. J. (2016). genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). In Annals of Oncology (Vol. 27, p. vi565). https://doi.org/10.1093/annonc/mdw435.22

Ravaud, A., R. J. Motzer, H. S. Pandha, M. Staehler, D. George, A. J. Pantuck, A. Patel, et al. “genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC).” In Annals of Oncology, 27:vi565, 2016. https://doi.org/10.1093/annonc/mdw435.22.

Ravaud A, Motzer RJ, Pandha HS, Staehler M, George D, Pantuck AJ, et al. genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). In: Annals of Oncology. 2016. p. vi565.

Ravaud, A., et al. “genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC).” Annals of Oncology, vol. 27, 2016, p. vi565. Scopus, doi:10.1093/annonc/mdw435.22.

Ravaud A, Motzer RJ, Pandha HS, Staehler M, George D, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lin X, Lechuga M, Martini JF, Patard JJ. genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). Annals of Oncology. 2016. p. vi565.